Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2008-08-06
2011-10-25
Chunduru, Prabha (Department: 1637)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C530S350000
Reexamination Certificate
active
08043815
ABSTRACT:
Provided are methods for determining whether an individual is a candidate to receive treatment with a DNA methylation inhibitor. The method can be performed a biological sample of cancerous tissue of the individual. Determining that PDEF expression is absent or low and survivin expression is present identifies the individual as a candidate to receive a treatment with a DNA methylation inhibitor. The method also includes communicating the result of identifying an individual as a candidate for receiving a DNA methylation inhibitor to a health care provider.
REFERENCES:
patent: 6692916 (2004-02-01), Bevilacqua et al.
patent: 2004/0048254 (2004-03-01), Olek et al.
patent: 2005/0026169 (2005-02-01), Cargill et al.
patent: 2007/0065859 (2007-03-01), Wang et al.
patent: 2008/0108081 (2008-05-01), Luke et al.
patent: 2005118875 (2005-12-01), None
Ghadersohi, A. et al. Prostate derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Res Treat., vol. 102, pp. 19-30, 2007, published on line Aug. 8, 2006.
Chavez-Blanco, A. et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell International, vol. vol. 6, No. 2, pp. 1-9, Jan. 31, 2006.
Ghadersohi et al. Prostate derived Ets transcription factor shows better tumor-association than other cancer associated molecules. Oncol. Rep., vol. 11(2), p. 1, abstract, 2004.
Wu, et al.; Molecular Mechanism of Inhibition of Survivin Transcription by the GC-rich Sequence-selective DNA Binding Antitumor Agent, Hedamycin; The Journal of Biological Chemistry, Issue of Mar. 11, 2005, vol. 280, No. 10; pp. 9745-9751.
Ghadersohi, et al.; Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo; Breast Cancer Res Treat (2007), vol. 102; pp. 19-30.
ISSA; DNA Methylation as a Therapeutic Target in Cancer; Clin Cancer Res., Mar. 15, 2007, vol. 13, No. 6; pp. 1634-1637.
Shah et al.; Selenium disrupts estogen receptor a signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells; Mol Cancer Ther, Aug. 2005, vol. 4, No. 8; pp. 1239-1249; Abstract.
Ghadersohi et al.; Prostate derived Ets transcription factor shows better tumor-association than other cancer-associated molecules; Oncol Rep., Feb. 2004, vol. 11, No. 2; 1 page; Abstract.
Feldman et al.; Pdef Expression in Human Breast Cancer Is Correlated with Invasive Potential and Altered Gene Expression; Cancer Research, Aug. 2003, vol. 63, No. 15; pp. 4626-4631; Abstract.
Apontes Pasha
Ghadersohi Ali
Li Fengzhi
Chunduru Prabha
Health Research , Inc.
Hodgson & Russ LLP
LandOfFree
Methods for analysis of PDEF and survivin as interconnected... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for analysis of PDEF and survivin as interconnected..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for analysis of PDEF and survivin as interconnected... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4269555